Resolution Therapeutics to present interim liver disease therapy data at AASLD
Resolution Therapeutics announced that interim data from its Phase I/II EMERALD study of RTX001, an engineered Regenerative Macrophage Therapy, has been accepted as a late-breaking presentation at the American Association for the Study of Liver Diseases meeting in Denver, Colorado, 5–9 Nov. 2026. EM
<p>Resolution Therapeutics announced that interim data from its Phase I/II EMERALD study of RTX001, an engineered Regenerative Macrophage Therapy, has been accepted as a late-breaking presentation at the American Association for the Study of Liver Diseases meeting in Denver, Colorado, 5–9 Nov. 2026. EM</p>